Hypophosphatasia

Hypophosphatasia (HPP) is an inherited metabolic disorder caused by loss-of-function mutations in the ALPL gene encoding tissue-nonspecific alkaline phosphatase (TNSALP), resulting in defective mineralization of bone and teeth.[1][2] TNSALP deficiency leads to extracellular accumulation of inorganic pyrophosphate (PPi), a potent inhibitor of hydroxyapatite crystal growth, which impairs skeletal and dental hard-tissue mineralization.[1][3] The signature oral radiographic pattern is alveolar bone loss—characteristically in the anterior mandible—with premature exfoliation of teeth bearing intact roots.[4][5] Severity ranges from lethal perinatal skeletal hypomineralization to isolated dental manifestations (odontohypophosphatasia).[1][6] Management is multidisciplinary; enzyme replacement therapy with asfotase alfa is approved for pediatric-onset forms.[7][8]

• Hypophosphatasia (HPP) is the current accepted term.[1][2]
• Odontohypophosphatasia (odonto-HPP) designates the mildest subtype, in which manifestations are confined to the dentition without skeletal disease.[4][6]
• Historical clinical subtypes—perinatal (severe and benign), infantile, childhood (severe and mild), adult, and odonto-HPP—are based on age at onset and presence of skeletal disease.
• Synonyms include deficiency of alkaline phosphatase and phosphoethanolaminuria.[11]
• The condition should not be confused with pseudohypophosphatasia, which shares clinical and radiographic features but shows normal serum ALP on standard assays.[4]

• Severe forms (perinatal and infantile HPP): estimated birth prevalence of ~1:100,000 in North America and ~1:300,000 in Europe.[4][10]
• Mild forms (childhood, adult, odonto-HPP): prevalence estimated as high as 1:508 in European populations, indicating substantial underdiagnosis.[4][12]
• The Canadian Mennonite and Hutterite populations carry a founder variant (p.Gly334Asp) with a carrier frequency of ~1:25 and perinatal HPP prevalence of ~1:2,500.[4]
• No consistent sex predilection exists, although one large pediatric cohort noted a male predominance in severe childhood HPP.[9]
• Dental manifestations occur across all subtypes and may be the presenting or sole feature.[4][13]

Dental manifestations

• Premature loss of primary teeth is the hallmark oral finding, typically occurring before age 3, with teeth exfoliating atraumatically with intact roots and minimal gingival inflammation.[5][13]
• Primary incisors are most commonly affected; however, any tooth may be involved.[4][9]
• Premature loss of permanent teeth and increased marginal bone loss also occur, particularly in adult-onset HPP.[12][13]
• Additional dental anomalies include small and bulbous crowns, cervical constriction, enamel hypoplasia and hypomineralization, dentin hypoplasia, enlarged pulp chambers, widened root canals, thin dentinal walls, increased caries, and tooth wear.[5][12][14]
• Enamel hypomineralization is significantly more common in non-odonto (severe) forms than in odonto-HPP.[15]
• Malocclusion, tooth agenesis, ankylosis, delayed eruption, and impaction have been reported.[12][15]

Skeletal and systemic manifestations

• Perinatal and infantile HPP: profound skeletal hypomineralization, rachitic changes, craniosynostosis, respiratory insufficiency, hypercalcemia, and pyridoxine-dependent seizures.[1][8]
• Childhood HPP: short stature, skeletal deformity, bone pain, fractures, and focal metaphyseal radiolucent "tongues".[1][4]
• Adult HPP: stress fractures (metatarsals, femoral pseudofractures), chondrocalcinosis, chronic musculoskeletal pain, fatigue, and osteomalacia.[4][8]

Biochemical hallmarks

• Persistently low serum ALP activity for age.[1][6]
• Elevated pyridoxal 5′-phosphate (PLP; sensitive and specific), elevated phosphoethanolamine (PEA), and elevated inorganic pyrophosphate (PPi).[1][8]

Location and distribution

• Alveolar bone loss characteristically involves the anterior mandible, with the central incisors lost first.[4]
• Any region of the jaws may be affected; involvement can be generalized in more severe forms.[4][5]
• In the appendicular skeleton, rachitic changes predominate at the metaphyses of long bones; in the skull, widened-appearing sutures, brachycephaly, and craniosynostosis may be seen.[4]

Periphery and shape of alveolar bone loss

• Alveolar bone loss appears as ill-defined resorption of the alveolar crest, often with a pattern resembling aggressive periodontal disease but characteristically lacking proportionate clinical inflammation.[5][13]
• The bone loss may be horizontal or vertical, progressing to complete loss of alveolar support around affected teeth.[4][5]

Internal architecture

• Alveolar bone hypomineralization is a characteristic finding on panoramic radiographs; quantitative pixel-value analysis demonstrates reduced alveolar bone density in the majority of odonto-HPP patients compared with age-matched controls.[16]
• Generalized osteopenia or osteoporosis of the jaws may be present, particularly in severe forms.[4]
• In the appendicular skeleton, focal metaphyseal radiolucent defects resembling "tongues" of lucency projecting from the growth plate into the metaphysis are fairly specific for childhood HPP.[4]

Effects on teeth

• Enlarged pulp chambers and widened root canals with thin dentinal walls are common, producing a "shell tooth" appearance on dental radiographs.[5][14]
• Teeth exfoliate with substantial remaining root structure and minimal or absent root resorption, a finding that distinguishes HPP from physiologic exfoliation and other causes of premature tooth loss.[5][17]
• Enamel and dentin hypoplasia or hypomineralization may reduce the radiodensity of tooth structure.[12][15]
• Short, abnormally shaped roots have been described.[14]

Effects on adjacent structures

• Loss of the lamina dura around affected teeth accompanies the alveolar bone destruction.[5]
• In infantile and childhood forms, the jaws may show generalized undermineralization consistent with the systemic skeletal phenotype.[4][16]
• Craniosynostosis produces premature fusion of calvarial sutures visible on skull radiographs in infantile HPP.[4]

Growth pattern and extent

• Alveolar bone loss is progressive; without treatment, it extends from the anterior mandible to involve additional teeth and regions.[4][5]
• Severity of jaw involvement generally correlates with the overall disease subtype: odonto-HPP shows localized alveolar changes, whereas infantile and childhood forms demonstrate widespread skeletal and dentoalveolar hypomineralization.[9][16]

Response to enzyme replacement therapy

• Alveolar bone mineralization may improve with asfotase alfa therapy; quantitative panoramic analysis has shown increased alveolar bone density in a subset of treated patients.[16]
• Skeletal rickets severity scores improve rapidly within the first 24 weeks of treatment, with sustained benefit beyond 3 years.[7]

Medical CT

• CT of the skull in infantile HPP demonstrates calvarial thinning, widened sutures, and craniosynostosis.[4]
• In severe forms, CT may reveal generalized undermineralization of the craniofacial skeleton, including the maxilla and mandible, providing a more detailed assessment of cortical thinning and bone density than conventional radiographs.[4]

Skeletal scintigraphy

• Bone scintigraphy may show decreased radiotracer uptake in areas of defective mineralization, reflecting impaired osteoblastic activity; however, this modality is not routinely used for diagnosis and adds limited information beyond biochemical and genetic testing.[1]

The differential for HPP in the jaws centers on conditions that produce premature tooth loss with alveolar bone destruction in children or generalized alveolar bone loss in adults, particularly when clinical inflammation is disproportionately mild relative to the degree of bone loss.

The highest-risk diagnostic pitfall is misdiagnosis as nutritional rickets or aggressive periodontitis, which may delay recognition of HPP and access to enzyme replacement therapy. Persistently low serum ALP—rather than elevated ALP as in other forms of rickets—is the cardinal discriminator and should prompt measurement of PLP and ALPL gene sequencing.[1][4][6]

Cementum

• Aplasia or marked hypoplasia of acellular extrinsic fiber cementum is the defining dental histopathologic finding and the primary mechanism of premature tooth loss; the deficient cementum fails to anchor periodontal ligament fibers to the root surface.[13][17][20]
• The cementum defect is variable even within the same patient: incisors and molars characteristically lack acellular cementum, whereas canines may retain apparently normal cementum.[17]
• Increased repair (cellular) cementum thickness has been observed in HPP teeth, possibly representing a compensatory response.[21]

Dentin

• Mantle dentin shows reduced mineral density (~10% reduction compared with controls), representing a novel mineralization defect distinct from the cementum abnormality.[17]
• Widened predentin, thin root dentin, and large-diameter dentinal tubules are reported.[14][18]
• Overall enamel and bulk dentin mineral densities are generally preserved.[17]

Alveolar bone

• Alveolar bone demonstrates defective mineralization with accumulation of unmineralized osteoid, consistent with the systemic osteomalacia of HPP.[3][22]
• Impaired alveolar bone socket healing after extraction has been demonstrated in animal models and is partially rescued by enzyme replacement therapy.[22]

Periodontal soft tissues

• Gingival tissues typically show minimal inflammatory infiltrate despite significant bone loss, distinguishing HPP from inflammatory periodontal disease.[5][18]

Molecular correlation

• All histopathologic findings trace to TNSALP deficiency and extracellular PPi accumulation, which inhibits hydroxyapatite crystal formation in cementum, dentin, and bone.[1][3]
• More than 400 predominantly missense ALPL mutations have been identified; biallelic mutations generally produce severe phenotypes, while monoallelic (dominant-negative) mutations produce milder disease.[23][24]

Diagnosis and workup

• Persistently low serum ALP activity for age is the biochemical hallmark; elevated PLP is the most sensitive and specific confirmatory marker.[1][8]
• ALPL gene sequencing confirms the diagnosis and is essential for recurrence risk assessment and prenatal counseling.[1][6]
• Dental practitioners may be the first to recognize mild HPP (odonto-HPP) based on unexplained premature tooth loss with intact roots; referral to metabolic bone specialists is indicated.[5][23]

Enzyme replacement therapy

• Asfotase alfa (Strensiq), a bone-targeted recombinant TNSALP, is approved for perinatal-, infantile-, and juvenile-onset HPP.[7][25]
• Administered subcutaneously at 6 mg/kg/week, it improves survival, skeletal mineralization, respiratory function, growth, and motor development in severely affected children.[7][26]
• Dental benefits include potential improvement in alveolar bone mineralization, though effects on cementum formation and long-term tooth retention require further study.[16][26]
• Injection-site reactions are the most common adverse effect; the therapy is generally well tolerated.[26][27]

Dental management

• Multidisciplinary dental care is essential, including pediatric dentistry, periodontics, prosthodontics, and oral surgery.[8][15]
• Conservative management of the remaining dentition with meticulous oral hygiene, fluoride therapy, and monitoring for caries is recommended.[5][15]
• Prosthetic rehabilitation (removable or implant-supported) may be necessary for patients with extensive tooth loss; implant outcomes in HPP are not well characterized.[15]
• Avoidance of bisphosphonates is critical, as these pyrophosphate analogs can worsen mineralization defects.[1][8]

Supportive care

• Calcium restriction in infants and children to manage hypercalcemia.[6]
• Monitoring for craniosynostosis, seizures, and respiratory compromise in severe pediatric forms.[4][8]
• Pain management, physical therapy, and psychological support for chronic musculoskeletal symptoms in adults.[8][27]

Prognosis

• Perinatal (severe) HPP carries high mortality without treatment; asfotase alfa has substantially improved survival.[7][26]
• Infantile HPP historically had ~50% mortality by 1 year without enzyme replacement.[7][10]
• Childhood, adult, and odonto-HPP have a more favorable skeletal prognosis but carry lifelong risk of progressive dental loss, fractures, and chronic pain.[4][8]
• Dental prognosis depends on disease severity and the degree of cementum and alveolar bone involvement; early diagnosis and multidisciplinary management improve outcomes.[5][15]

Genetic counseling

• Severe HPP (perinatal and infantile) follows autosomal recessive inheritance; milder forms may be autosomal dominant or recessive.[1][6]
• Carrier frequency for ALPL pathogenic variants is estimated at ~1:150 in North America and ~1:275 in Europe.[4]
• Prenatal diagnosis is available through ALPL sequencing when familial variants are known.[1][4]

Pediatric considerations

• Premature loss of primary teeth before age 3 should prompt evaluation of serum ALP, as this may be the first clinical sign of HPP.[5][23]
• Childhood HPP may be misdiagnosed as non-accidental trauma, idiopathic juvenile osteoporosis, or nutritional rickets; serial ALP measurement and awareness of the low-ALP hallmark prevent diagnostic delay.[4][23]

Odontohypophosphatasia as a sentinel diagnosis

• Isolated dental manifestations may precede recognition of systemic metabolic disease by years or decades; dental professionals play a critical role in early identification.[5][13]
• Adult patients initially diagnosed with "early-onset periodontitis" who have disproportionately low inflammation relative to bone loss should be screened for HPP with serum ALP.[13][18]